The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The San Francisco-based startup, which closed a $5 million Series A round in 2017, aims to develop nutritionally enhanced food and feed crops.
Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
A new analysis finds some cancers receive more nonprofit dollars than others.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.